-
Hengrui Medicine Gets Green Light from NMPA for Two Anti-Cancer Drugs
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that it has received separate clinical trial approvals from the National Medical Products Administration (NMPA) for two of its drug candidates, SHR-3276 and HRS2398. SHR-3276 is slated for study in patients with general advanced solid…
-
Bayer CEO Joins German Chancellor on China Visit, Announces New Investments
•
Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a multinational pharmaceutical and life sciences company based in Germany, recently had its CEO, Bill Anderson, accompany German Chancellor Olaf Scholz on a high-profile visit to China. In a brief interview with Xinhua, Anderson emphasized Bayer’s dedication to developing innovative drugs and…
-
GSK’s Gepotidacin Shows Non-Inferior Efficacy in Phase III Gonorrhoea Tria
•
GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK), a leading UK pharmaceutical company, last week announced positive results from a Phase III clinical trial for gepotidacin, a first-in-class triazaacenaphthylene antibiotic, in the treatment of uncomplicated urogenital gonorrhoea (GC). The study demonstrated non-inferiority to the standard azithromycin-based treatment, with a microbiological response rate…
-
Joincare Pharmaceutical’s TG-1000 Shows Promise in Phase III Flu Treatment Trial
•
Joincare Pharmaceutical Group Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has reportedly completed the unblinding of a Phase III trial for TG-1000, an investigational influenza antiviral drug. The trial has shown positive preliminary data, indicating that the company is now preparing to file a New Drug Application (NDA) in…
-
Kind Pharmaceuticals Resolves Trade Secrets Dispute with Fibrogen Amid HIF-PHI Pipeline Development
•
Kind Pharmaceuticals LLC, a Sino-US pharmaceutical company, along with its Chinese affiliate Hangzhou Andao Pharmaceutical Ltd, has announced an amicable resolution to a trade secrets dispute with Fibrogen Inc. (NASDAQ: FGEN). The dispute originated from a lawsuit initiated by Fibrogen in November 2022 against Andao, Kind Pharma, and individual defendants…
-
Roche’s Alecensa approved by FDA as First ALK Inhibitor for Adjuvant Treatment of NSCLC
•
Roche Holding AG (SWX: ROG; OTCMKTS: RHHBY), a Swiss multinational healthcare company, announced last week that the US Food and Drug Administration (FDA) has granted regulatory approval for Alecensa (alectinib) as an adjuvant treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). This marks the first approval of an…
-
Takeda Scores FDA Nod for Subcutaneous Vedolizumab to Treat Inflammatory Bowel Disease
•
The US Food and Drug Administration (FDA) has granted Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese pharmaceutical company, registration authorization for a subcutaneous formulation of its alpha4beta7 integrin antagonist Entyvio (vedolizumab). This new formulation is intended for use as a maintenance therapy in patients with moderately to severely active…
-
CareRay Digital Medical Invests $15 Million for Stake in X-Ray Detector Maker ISID
•
CareRay Digital Medical Technology Co., Ltd, a leading medical technology company based in Jiangsu, has acquired a 30% stake in ISID Ltd, a London-based developer and manufacturer of high-end X-ray flat panel detectors and CMOS sensors, for a consideration of GBP 12 million (USD 15 million). ISID specializes in the…
